Australia Stock Exchange release from ORTHOCELL : Regulatory Approval for Remplir Nerve Repair Device
20/03/2022 23:25
Australia Stock Exchange release from ORTHOCELL OCC.AX : Regulatory Approval for Remplir Nerve Repair Device
Recent news on Orthocell
See all newsBrief: Orthocell Reports September Quarter Revenue Of A$3.6 Million
Australia's Orthocell rises as flagship product records first Thailand sales
Brief: Orthocell Says QTRLY A$3.2 Million Revenue Achieved
Australia's Orthocell set for best week since November 2024 on US DoD approval for key product
Brief: Orthocell's First Surgical Use Of Remplir In US Department Of Defense